Eric Van Cutsem

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Debucquoy Annelies; Roels Sarah; Goethals Laurence; Libbrecht Louis; Van Cutsem Eric; Geboes Karel; Penninckx Freddy; D'Hoore André; McBride William H; Haustermans Karin
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier M-A; Canon J-L; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Jacobs Bart; De Roock Wendy; Piessevaux Hubert; Van Oirbeek Robin; Biesmans Bart; De Schutter Jef; Fieuws Steffen; Vandesompele Jo; Peeters Marc; Van Laethem Jean-Luc; Humblet Yves; Pénault-Llorca Frederique; De Hertogh Gert; Laurent-Puig Pierre; Van Cutsem Eric; Tejpar Sabine
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Eric Van Cutsem (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Debucquoy Annelies; Roels Sarah; Goethals Laurence; Libbrecht Louis; Van Cutsem Eric; Geboes Karel; Penninckx Freddy; D'Hoore André; McBride William H; Haustermans Karin
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;93(2):273-8.
2009: Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier M-A; Canon J-L; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(11):1842-7.
2009: Jacobs Bart; De Roock Wendy; Piessevaux Hubert; Van Oirbeek Robin; Biesmans Bart; De Schutter Jef; Fieuws Steffen; Vandesompele Jo; Peeters Marc; Van Laethem Jean-Luc; Humblet Yves; Pénault-Llorca Frederique; De Hertogh Gert; Laurent-Puig Pierre; Van Cutsem Eric; Tejpar Sabine
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5068-74.
2009: Segaert Siegfried; Chiritescu Gabriela; Lemmens Liesbeth; Dumon Kristien; Van Cutsem Eric; Tejpar Sabine
Skin toxicities of targeted therapies.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():295-308.
2009: Prenen Hans; Tejpar Sabine; Van Cutsem Eric
Impact of molecular markers on treatment selection in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():70-8.
2009: Valentini Vincenzo; Aristei Cynthia; Glimelius Bengt; Minsky Bruce D; Beets-Tan Regina; Borras Jose M; Haustermans Karin; Maingon Philippe; Overgaard Jens; Pahlman Lars; Quirke Phil; Schmoll Hans-Joachim; Sebag-Montefiore David; Taylor Irving; Van Cutsem Eric; Van de Velde Cornelius; Cellini Numa; Latini Paolo;
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2).
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;92(2):148-63.
2009: Piessevaux H; Buyse M; De Roock W; Prenen H; Schlichting M; Van Cutsem E; Tejpar S
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1375-82.
2009: Van Cutsem Eric; Labianca Roberto; Bodoky György; Barone Carlo; Aranda Enrique; Nordlinger Bernard; Topham Claire; Tabernero Josep; André Thierry; Sobrero Alberto F; Mini Enrico; Greil Richard; Di Costanzo Francesco; Collette Laurence; Cisar Laura; Zhang Xiaoxi; Khayat David; Bokemeyer Carsten; Roth Arnaud D; Cunningham David
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3117-25.
2009: Verslype C; Van Cutsem E; Dicato M; Arber N; Berlin J D; Cunningham D; De Gramont A; Diaz-Rubio E; Ducreux M; Gruenberger T; Haller D; Haustermans K; Hoff P; Kerr D; Labianca R; Moore M; Nordlinger B; Ohtsu A; Rougier P; Scheithauer W; Schmoll H-J; Sobrero A; Tabernero J; van de Velde C
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 7():vii1-vii6.
2009: Van Cutsem E; Oliveira J;
Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():61-3.
2009: Van Cutsem E; Oliveira J;
Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():49-50.
2009: Prenen Hans; De Schutter Jef; Jacobs Bart; De Roock Wendy; Biesmans Bart; Claes Bart; Lambrechts Diether; Van Cutsem Eric; Tejpar Sabine
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3184-8.
2009: Van Cutsem Eric; Vervenne Walter L; Bennouna Jaafar; Humblet Yves; Gill Sharlene; Van Laethem Jean-Luc; Verslype Chris; Scheithauer Werner; Shang Aijing; Cosaert Jan; Moore Malcolm J
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2231-7.
2009: Van Cutsem Eric; Köhne Claus-Henning; Hitre Erika; Zaluski Jerzy; Chang Chien Chung-Rong; Makhson Anatoly; D'Haens Geert; Pintér Tamás; Lim Robert; Bodoky György; Roh Jae Kyung; Folprecht Gunnar; Ruff Paul; Stroh Christopher; Tejpar Sabine; Schlichting Michael; Nippgen Johannes; Rougier Philippe
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
The New England journal of medicine 2009;360(14):1408-17.
2009: Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem Ph; Van Laethem J L; Van Cutsem E
The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Acta gastro-enterologica Belgica 2009;72(1):54-8.
2009: Dero I; De Pauw M; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Roeyen G; Van Cutsem E; Van Hootegem Ph; Van Laethem J L; Verslype C; Peeters M
Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
Acta gastro-enterologica Belgica 2009;72(1):34-8.
2009: Borbath I; Jamar F; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem Ph; Van Laethem J L; Verslype C; Pauwels S
Diagnostic pitfalls in digestive neuroendocrine tumours.
Acta gastro-enterologica Belgica 2009;72(1):29-33.
2009: Di Fiore Frédéric; Van Cutsem Eric
Acute and long-term gastrointestinal consequences of chemotherapy.
Best practice & research. Clinical gastroenterology 2009;23(1):113-24.
2008: Mitry Emmanuel; Fields Anthony L A; Bleiberg Harry; Labianca Roberto; Portier Guillaume; Tu Dongsheng; Nitti Donato; Torri Valter; Elias Dominique; O'Callaghan Chris; Langer Bernard; Martignoni Giancarlo; Bouché Olivier; Lazorthes Franck; Van Cutsem Eric; Bedenne Laurent; Moore Malcolm J; Rougier Philippe
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4906-11.
2008: Vansteenkiste Johan; Van Cutsem Eric; Dumez Herlinde; Chen Cong; Ricker Justin L; Randolph Sophia S; Schöffski Patrick
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Investigational new drugs 2008;26(5):483-8.
2008: Personeni Nicola; Fieuws Steffen; Piessevaux Hubert; De Hertogh Gert; De Schutter Jef; Biesmans Bart; De Roock Wendy; Capoen An; Debiec-Rychter Maria; Van Laethem Jean-Luc; Peeters Marc; Humblet Yves; Van Cutsem Eric; Tejpar Sabine
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5869-76.
2008: Bielen Didier; Vanslembrouck Ragna; De Keyzer Frederik; Vandenhout Hilde; Guendel Lutz; Van Cutsem Eric; Marchal Guy
Computed tomographic colonography: automated tool for polyp measurement delivering on patient risk stratification.
Journal of computer assisted tomography 2008;32(4):504-10.
2008: Van Cutsem E; Dicato M; Haustermans K; Arber N; Bosset J-F; Cunningham D; De Gramont A; Diaz-Rubio E; Ducreux M; Goldberg R; Glynne-Jones R; Haller D; Kang Y-K; Kerr D; Labianca R; Minsky B D; Moore M; Nordlinger B; Rougier P; Scheithauer W; Schmoll H-J; Sobrero A; Tabernero J; Tempero M; Van de Velde C; Zalcberg J
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 6():vi1-8.
2008: Cassidy Jim; Schmoll Hans-Joachim; Van Cutsem Eric
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2226-7; author reply 2228.
2008: Haller Daniel G; Cassidy Jim; Clarke Stephen J; Cunningham David; Van Cutsem Eric; Hoff Paulo M; Rothenberg Mace L; Saltz Leonard B; Schmoll Hans-Joachim; Allegra Carmen; Bertino Joseph R; Douillard Jean-Yves; Gustavsson Bengt G; Milano Gerard; O'Connell Michael; Rustum Youcef; Tabernero Josep; Gilberg Frank; Sirzén Florin; Twelves Chris
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2118-23.
2008: Amado Rafael G; Wolf Michael; Peeters Marc; Van Cutsem Eric; Siena Salvatore; Freeman Daniel J; Juan Todd; Sikorski Robert; Suggs Sid; Radinsky Robert; Patterson Scott D; Chang David D
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1626-34.
2008: Nordlinger Bernard; Sorbye Halfdan; Glimelius Bengt; Poston Graeme J; Schlag Peter M; Rougier Philippe; Bechstein Wolf O; Primrose John N; Walpole Euan T; Finch-Jones Meg; Jaeck Daniel; Mirza Darius; Parks Rowan W; Collette Laurence; Praet Michel; Bethe Ullrich; Van Cutsem Eric; Scheithauer Werner; Gruenberger Thomas;
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Lancet 2008;371(9617):1007-16.
2008: Folprecht Gunnar; Seymour Matthew T; Saltz Leonard; Douillard Jean-Yves; Hecker Hartmut; Stephens Richard J; Maughan Timothy S; Van Cutsem Eric; Rougier Philippe; Mitry Emmanuel; Schubert Ute; Köhne Claus-Henning
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1443-51.
2008: De Roock W; Piessevaux H; De Schutter J; Janssens M; De Hertogh G; Personeni N; Biesmans B; Van Laethem J-L; Peeters M; Humblet Y; Van Cutsem E; Tejpar S
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):508-15.
2008: Van Cutsem E; Verslype C; Beale P; Clarke S; Bugat R; Rakhit A; Fettner S H; Brennscheidt U; Feyereislova A; Delord J-P
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):332-9.
2008: Wiedenmann Bertram; Malfertheiner Peter; Friess Helmut; Ritch Paul; Arseneau James; Mantovani Giovanni; Caprioni Francesco; Van Cutsem Eric; Richel Dirk; DeWitte Mark; Qi Ming; Robinson Don; Zhong Bob; De Boer Carla; Lu J D; Prabhakar Uma; Corringham Robert; Von Hoff Daniel
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
The journal of supportive oncology 2008;6(1):18-25.
2008: Van Cutsem Eric; Van de Velde Cornelius; Roth Arnaud; Lordick Florian; Köhne Claus-Henning; Cascinu Stefano; Aapro Matti;
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
European journal of cancer (Oxford, England : 1990) 2008;44(2):182-94.
2008: Van Cutsem E; Siena S; Humblet Y; Canon J-L; Maurel J; Bajetta E; Neyns B; Kotasek D; Santoro A; Scheithauer W; Spadafora S; Amado R G; Hogan N; Peeters M
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(1):92-8.
2008: Budiharto Tom; Haustermans Karin; Van Cutsem Eric; Van Steenbergen Werner; Topal Baki; Aerts Raymond; Ectors Nadine; Bielen Didier; Vanbeckevoort Dirk; Goethals Laurence; Verslype Chris
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Radiation oncology (London, England) 2008;3():30.
2008: Verslype C; Prenen H; Van Cutsem E
The role of chemotherapy in biliary tract carcinoma.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2008;10(3):164-7.
2007: Siena S; Peeters M; Van Cutsem E; Humblet Y; Conte P; Bajetta E; Comandini D; Bodoky G; Van Hazel G; Salek T; Wolf M; Devercelli G; Woolley M; Amado R G
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
British journal of cancer 2007;97(11):1469-74.
2007: Tabernero Josep; Van Cutsem Eric; Díaz-Rubio Eduardo; Cervantes Andrés; Humblet Yves; André Thierry; Van Laethem Jean-Luc; Soulié Patrick; Casado Esther; Verslype Chris; Valera Javier Sastre; Tortora Giampaolo; Ciardiello Fortunato; Kisker Oliver; de Gramont Aimery
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5225-32.
2007: Smeenk Hans G; van Eijck Casper H J; Hop Wim C; Erdmann Joris; Tran Kheetje C K; Debois Muriel; van Cutsem Eric; van Dekken Herman; Klinkenbijl Jean H; Jeekel Johannes
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891.
Annals of surgery 2007;246(5):734-40.
2007: Segaert Siegfried; Van Cutsem Eric
Clinical management of EGFRI dermatologic toxicities: the European perspective.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):22-6.
2007: Perez-Soler Roman; Van Cutsem Eric
Clinical research of EGFR inhibitors and related dermatologic toxicities.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):10-6.
2007: Mitchell Edith P; Perez-Soler Roman; Van Cutsem Eric; Lacouture Mario E
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):4-9.
2007: Van Cutsem Eric
Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer.
Clinical colorectal cancer 2007;6 Suppl 2():S60-5.
2007: Nordlinger Bernard; Van Cutsem Eric; Rougier Philippe; Köhne Claus-Henning; Ychou Marc; Sobrero Alberto; Adam Rene; Arvidsson Dag; Carrato Alfredo; Georgoulias Vassilis; Giuliante Felice; Glimelius Bengt; Golling Markus; Gruenberger Thomas; Tabernero Josep; Wasan Harpreet; Poston Graeme;
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2037-45.
2007: Lagergren Pernilla; Fayers Peter; Conroy Thierry; Stein Hubert J; Sezer Orhan; Hardwick Richard; Hammerlid Eva; Bottomley Andrew; Van Cutsem Eric; Blazeby Jane M;
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2066-73.
2007: Van Cutsem Eric
Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer.
Clinical advances in hematology & oncology : H&O 2007;5(8):611-3.
2007: Groenestege Wouter M Tiel; Thébault Stéphanie; van der Wijst Jenny; van den Berg Dennis; Janssen Rob; Tejpar Sabine; van den Heuvel Lambertus P; van Cutsem Eric; Hoenderop Joost G; Knoers Nine V; Bindels René J
Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.
The Journal of clinical investigation 2007;117(8):2260-7.
2007: Ajani Jaffer A; Moiseyenko Vladimir M; Tjulandin Sergei; Majlis Alejandro; Constenla Manuel; Boni Corrado; Rodrigues Adriano; Fodor Miguel; Chao Yee; Voznyi Edouard; Awad Lucile; Van Cutsem Eric;
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3210-6.
2007: Ajani Jaffer A; Moiseyenko Vladimir M; Tjulandin Sergei; Majlis Alejandro; Constenla Manuel; Boni Corrado; Rodrigues Adriano; Fodor Miguel; Chao Yee; Voznyi Edouard; Marabotti Cindy; Van Cutsem Eric;
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(22):3205-9.
2007: Verslype C; Van Cutsem E; Dicato M; Cascinu S; Cunningham D; Diaz-Rubio E; Glimelius B; Haller D; Haustermans K; Heinemann V; Hoff P; Johnston P G; Kerr D; Labianca R; Louvet C; Minsky B; Moore M; Nordlinger B; Pedrazzoli S; Roth A; Rothenberg M; Rougier P; Schmoll H-J; Tabernero J; Tempero M; van de Velde C; Van Laethem J-L; Zalcberg J
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 7():vii1-vii10.
2007: Lutz Manfred P; Wilke Hansjochen; Wagener D J Theo; Vanhoefer Udo; Jeziorski Krzysztof; Hegewisch-Becker Susanna; Balleisen Leopold; Joossens Eric; Jansen Rob L; Debois Muriel; Bethe Ullrich; Praet Michel; Wils Jacques; Van Cutsem Eric;
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2580-5.
2007: Farroni Nadia; Van den Bosch Anita; Haustermans Karin; Van Cutsem Eric; Moons Philip; D'hoore André; Penninckx Freddy
Perineal colostomy with appendicostomy as an alternative for an abdominal colostomy: symptoms, functional status, quality of life, and perceived health.
Diseases of the colon and rectum 2007;50(6):817-24.
2007: Van Cutsem Eric; Peeters Marc; Siena Salvatore; Humblet Yves; Hendlisz Alain; Neyns Bart; Canon Jean-Luc; Van Laethem Jean-Luc; Maurel Joan; Richardson Gary; Wolf Michael; Amado Rafael G
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1658-64.
2007: Tejpar Sabine; Piessevaux Hubert; Claes Kathleen; Piront Patricia; Hoenderop Joost G J; Verslype Chris; Van Cutsem Eric
Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
The lancet oncology 2007;8(5):387-94.
2007: Van Cutsem Eric; Verslype Chris; Grusenmeyer Patrick A
Lessons learned in the management of advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):1949-52.
2007: Machiels J-P; Sempoux C; Scalliet P; Coche J-C; Humblet Y; Van Cutsem E; Kerger J; Canon J-L; Peeters M; Aydin S; Laurent S; Kartheuser A; Coster B; Roels S; Daisne J-F; Honhon B; Duck L; Kirkove C; Bonny M-A; Haustermans K
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):738-44.
2007: Goldberg Richard M; Rothenberg Mace L; Van Cutsem Eric; Benson Al B; Blanke Charles D; Diasio Robert B; Grothey Axel; Lenz Heinz-Josef; Meropol Neal J; Ramanathan Ramesh K; Becerra Carlos H Roberto; Wickham Rita; Armstrong Delma; Viele Carol
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
The oncologist 2007;12(1):38-50.
2007: Schmoll Hans-Joachim; Cartwright Thomas; Tabernero Josep; Nowacki Marek P; Figer Arie; Maroun Jean; Price Timothy; Lim Robert; Van Cutsem Eric; Park Young-Suk; McKendrick Joseph; Topham Claire; Soler-Gonzalez Gemma; de Braud Filipo; Hill Mark; Sirzén Florin; Haller Daniel G
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):102-9.
2007: Van Cutsem Eric; Geboes Karen
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Best practice & research. Clinical gastroenterology 2007;21(6):1089-108.
2007: Fensterer Heiko; Radlwimmer Bernhard; Sträter Jörn; Buchholz Malte; Aust Daniela E; Julié Catherine; Radvanyi François; Nordlinger Bernard; Belluco Claudio; Van Cutsem Eric; Köhne Claus-Henning; Kestler Hans A; Schwaenen Carsten; Nessling Michelle; Lutz Manfred P; Lichter Peter; Gress Thomas M;
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.
BMC cancer 2007;7():58.
2006: Van Cutsem Eric; Moiseyenko Vladimir M; Tjulandin Sergei; Majlis Alejandro; Constenla Manuel; Boni Corrado; Rodrigues Adriano; Fodor Miguel; Chao Yee; Voznyi Edouard; Risse Marie-Laure; Ajani Jaffer A;
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(31):4991-7.
2006: Goddeeris Karel; Verslype Chris; Wilms Guido; Van Cutsem Eric
Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature.
Acta gastro-enterologica Belgica 2006;69(4):377-80.
2006: Lenz Heinz-Josef; Van Cutsem Eric; Khambata-Ford Shirin; Mayer Robert J; Gold Philip; Stella Philip; Mirtsching Barry; Cohn Allen L; Pippas Andrew W; Azarnia Nozar; Tsuchihashi Zenta; Mauro David J; Rowinsky Eric K
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4914-21.
2006: Van Cutsem Eric
Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
The oncologist 2006;11(9):1010-7.
2006: Rojo Federico; Tabernero Josep; Albanell Joan; Van Cutsem Eric; Ohtsu Atsushi; Doi Toshihiko; Koizumi Wasaburo; Shirao Kuniaki; Takiuchi Hiroya; Ramon y Cajal S; Baselga José
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4309-16.
2006: Van Cutsem Eric; Nordlinger Bernard; Adam Rene; Köhne Claus-Henning; Pozzo Carmelo; Poston Graeme; Ychou Marc; Rougier Philippe;
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
European journal of cancer (Oxford, England : 1990) 2006;42(14):2212-21.
2006: Van Cutsem Eric
Progress with biological agents in metastatic colorectal cancer leads to many challenges.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3325-7.
2006: Van Cutsem E; Dicato M; Arber N; Benson A; Cunningham D; Diaz-Rubio E; Glimelius B; Goldberg R; Haller D; Haustermans K; Koo-Kang Y; Labianca R; Lang I; Minsky B; Nordlinger B; Roth A; Rougier P; Schmoll H-J; Sobrero A; Tabernero J; Szawlowski A; van de Velde C
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 6():vi13-8.
2006: Van Schaeybroeck Sandra; Kyula Joan; Kelly Donal M; Karaiskou-McCaul Anthi; Stokesberry Susan A; Van Cutsem Eric; Longley Daniel B; Johnston Patrick G
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Molecular cancer therapeutics 2006;5(5):1154-65.
2006: Efficace Fabio; Bottomley Andrew; Coens Corneel; Van Steen Kristel; Conroy Thierry; Schöffski Patrick; Schmoll Hans; Van Cutsem Eric; Köhne Claus-Henning
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
European journal of cancer (Oxford, England : 1990) 2006;42(1):42-9.
2006: Spaepen M; Vankeirsbilck B; Van Opstal S; Tejpar S; Van Cutsem E; Geboes K; Legius E; Matthijs G
Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients.
Familial cancer 2006;5(2):179-89.
2005: Lutz Manfred P; Van Cutsem Eric; Wagener Theo; Van Laethem Jean-Luc; Vanhoefer Udo; Wils Jacques A; Gamelin Eric; Koehne Claus H; Arnaud Jean P; Mitry Emmanuel; Husseini Faress; Reichardt Peter; El-Serafi Mustafa; Etienne Pierre-Luc; Lingenfelser Thomas; Praet Michel; Genicot Bruno; Debois Muriel; Nordlinger Bernard; Ducreux Michel P;
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9250-6.
2005: Van Cutsem Eric; Costa Frederico
Progress in the adjuvant treatment of colon cancer: has it influenced clinical practice?
JAMA : the journal of the American Medical Association 2005;294(21):2758-60.
2005: Goethals L; Haustermans K; Perneel C; Bussels B; D'Hoore A; Geboes K; Ectors N; Van Cutsem E; Van den Bogaert W; Penninckx F
Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2005;31(9):969-76.
2005: Van Schaeybroeck Sandra; Karaiskou-McCaul Anthi; Kelly Donal; Longley Daniel; Galligan Leeona; Van Cutsem Eric; Johnston Patrick
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7480-9.
2005: Valentini Vincenzo; Glimelius Bengt; Minsky Bruce D; Van Cutsem Eric; Bartelink Hanry; Beets-Tan Regina G H; Gerard Jean-Pierre; Kosmidis Paris; Pahlman Lars; Picciocchi Aurelio; Quirke Phil; Tepper Joel; Tonato Maurizio; Van de Velde Cornelius J; Cellini Numa; Latini Paolo
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;76(3):241-50.
2005: Segaert S; Van Cutsem E
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(9):1425-33.
2005: Ajani Jaffer A; Fodor Miguel B; Tjulandin Sergei A; Moiseyenko Vladimir M; Chao Yee; Cabral Filho Sebastiao; Majlis Alejandro; Assadourian Sylvie; Van Cutsem Eric
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5660-7.
2005: Segaert Siegfried; Tabernero Josep; Chosidow Olivier; Dirschka Thomas; Elsner Joern; Mancini Luca; Maughan Tim; Morere Jean-Fran Ois; Santoro Armando; Sobrero Alberto; Van Cutsem Eric; Layton Alison
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2005;3(8):599-606.
2005: Köhne C-H; van Cutsem E; Wils J; Bokemeyer C; El-Serafi M; Lutz M P; Lorenz M; Reichardt P; Rückle-Lanz H; Frickhofen N; Fuchs R; Mergenthaler H-G; Langenbuch T; Vanhoefer U; Rougier P; Voigtmann R; Müller L; Genicot B; Anak O; Nordlinger B;
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4856-65.
2005: Twelves Chris J; Butts Charles A; Cassidy Jim; Conroy Thierry; Braud Fillippo de; Diaz-Rubio Eduardo; Tabernero Josep M; Schoffski Patrick; Figer Arie; Brunet Rene; Grossmann Johannes; Sobrero Alberto F; Van Cutsem Eric J
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Clinical colorectal cancer 2005;5(2):101-7.
2005: Nordlinger Bernard; Rougier Philippe; Arnaud Jean-Pierre; Debois Muriel; Wils Jaques; Ollier Jean-Claude; Grobost Olivier; Lasser Philippe; Wals Jacob; Lacourt Jerome; Seitz Jean-François; Guimares dos Santos Jose; Bleiberg Harry; Mackiewickz Rémy; Conroy Thierry; Bouché Olivier; Morin Thierry; Baila Liliana; van Cutsem Eric; Bedenne Laurent
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
The lancet oncology 2005;6(7):459-68.
2005: Catalano Vincenzo; Labianca Roberto; Beretta Giordano D; Gatta Gemma; de Braud Filippo; Van Cutsem Eric
Gastric cancer.
Critical reviews in oncology/hematology 2005;54(3):209-41.
2005: Van Cutsem E; Dirix L; Van Laethem J-L; Van Belle S; Borner M; Gonzalez Baron M; Roth A; Morant R; Joosens E; Gruia G; Sibaud D; Bleiberg H
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
British journal of cancer 2005;92(6):1055-62.
2005: Van Cutsem Eric; Verslype Chris; Tejpar Sabine
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Seminars in oncology 2005;32(1):43-51.
2005: Ducreux M; Van Cutsem E; Van Laethem J L; Gress T M; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B;
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
European journal of cancer (Oxford, England : 1990) 2005;41(3):398-403.
2005: Michils Geneviève; Tejpar Sabine; Thoelen Reinhilde; van Cutsem Eric; Vermeesch Joris Robert; Fryns Jean-Pierre; Legius Eric; Matthijs Gert
Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study.
Human mutation 2005;25(2):125-34.
2005: Van Cutsem Eric; Arends Jann
The causes and consequences of cancer-associated malnutrition.
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2005;9 Suppl 2():S51-63.
2005: de Gramont Aimery; Van Cutsem Eric
Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
Oncology 2005;69 Suppl 3():46-56.
2004: Van Cutsem Eric
Can the addition of bevacizumab to IFL chemotherapy improve outcome in colorectal cancer?
Nature clinical practice. Gastroenterology & hepatology 2004;1(2):72-3.
2004: Vrieze Olga; Haustermans Karin; De Wever Walter; Lerut Toni; Van Cutsem Eric; Ectors Nadine; Hiele Martin; Flamen Patrick
Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2004;73(3):269-75.
2004: Blazeby J M; Conroy T; Bottomley A; Vickery C; Arraras J; Sezer O; Moore J; Koller M; Turhal N S; Stuart R; Van Cutsem E; D'haese S; Coens C;
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(15):2260-8.
2004: Benson Al B; Schrag Deborah; Somerfield Mark R; Cohen Alfred M; Figueredo Alvaro T; Flynn Patrick J; Krzyzanowska Monika K; Maroun Jean; McAllister Pamela; Van Cutsem Eric; Brouwers Melissa; Charette Manya; Haller Daniel G
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3408-19.
2004: Cunningham David; Humblet Yves; Siena Salvatore; Khayat David; Bleiberg Harry; Santoro Armando; Bets Danny; Mueser Matthias; Harstrick Andreas; Verslype Chris; Chau Ian; Van Cutsem Eric
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England journal of medicine 2004;351(4):337-45.
2004: Cassidy Jim; Tabernero Josep; Twelves Chris; Brunet René; Butts Charles; Conroy Thierry; Debraud Filippo; Figer Arie; Grossmann Johannes; Sawada Noriaki; Schöffski Patrick; Sobrero Alberto; Van Cutsem Eric; Díaz-Rubio Eduardo
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2084-91.
2004: Van Cutsem E; van de Velde H; Karasek P; Oettle H; Vervenne W L; Szawlowski A; Schoffski P; Post S; Verslype C; Neumann H; Safran H; Humblet Y; Perez Ruixo J; Ma Y; Von Hoff D
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1430-8.
2004: Van Cutsem Eric; Aerts Raymond; Haustermans Karin; Topal Baki; Van Steenbergen Werner; Verslype Chris
Systemic treatment of pancreatic cancer.
European journal of gastroenterology & hepatology 2004;16(3):265-74.
2004: Van Cutsem E; Hoff P M; Harper P; Bukowski R M; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun J A; Marshall J L; Mitchell E P; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky R L
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
British journal of cancer 2004;90(6):1190-7.
2004: Ruszniewski Philippe; Ish-Shalom Sofia; Wymenga Machteld; O'Toole Dermot; Arnold Rudolf; Tomassetti Paola; Bax Nigel; Caplin Martyn; Eriksson Barbro; Glaser Benjamin; Ducreux Michel; Lombard-Bohas Catherine; de Herder Wouter W; Delle Fave Gianfranco; Reed Nick; Seitz Jean François; Van Cutsem Eric; Grossman Ashley; Rougier Philippe; Schmidt Wolfgang; Wiedenmann Bertram
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Neuroendocrinology 2004;80(4):244-51.
2004: Marsé Hilde; Van Cutsem Eric; Grothey Axel; Valverde Sonia
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2004;8 Suppl 1():S16-30.
2004: Van Cutsem Eric
The treatment of advanced gastric cancer: new findings on the activity of the taxanes.
The oncologist 2004;9 Suppl 2():9-15.
2003: Thomeer Maarten; Carbone Iacopo; Bosmans Hilde; Kiss Gabriel; Bielen Didier; Vanbeckevoort Dirk; Van Cutsem Eric; Rutgeerts Paul; Marchal Guy
Stool tagging applied in thin-slice multidetector computed tomography colonography.
Journal of computer assisted tomography 2003;27(2):132-9.
2003: Tejpar S; van Cutsem E
Molecular defects in colorectal tumorigenesis.
Drugs of today (Barcelona, Spain : 1998) 2003;39 Suppl C():111-8.
2003: Douillard J-Y; Sobrero A; Carnaghi C; Comella P; Díaz-Rubio E; Santoro A; Van Cutsem E
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14 Suppl 2():ii7-12.
2002: Michils Geneviève; Tejpar Sabine; Fryns Jean-Pierre; Legius Eric; Van Cutsem Eric; Cassiman Jean-Jacques; Matthijs Gert
Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD).
European journal of human genetics : EJHG 2002;10(9):505-10.
2002: Van Cutsem E; Dicato M; Wils J; Cunningham D; Diaz-Rubio E; Glimelius B; Haller D; Johnston P; Kerr D; Koehne C H; Labianca R; Minsky B; Nordlinger B; Roth A; Rougier P; Schmoll H J
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).
European journal of cancer (Oxford, England : 1990) 2002;38(11):1429-36.
2002: Thomeer M; Bielen D; Vanbeckevoort D; Dymarkowski S; Gevers A; Rutgeerts P; Hiele M; Van Cutsem E; Marchal G
Patient acceptance for CT colonography: what is the real issue?
European radiology 2002;12(6):1410-5.
2002: Conroy T; Etienne P L; Adenis A; Ducreux M; Paillot B; Oliveira J; Seitz J F; Francois E; Van Cutsem E; Wagener D J T; Kohser F; Daamen S; Praet M; Gorlia T; Baron B; Wils J;
Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):721-9.
2002: Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky R L;
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):566-75.
2002: Van Cutsem E; Cunningham D; Maroun J; Cervantes A; Glimelius B
Raltitrexed: current clinical status and future directions.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):513-22.
2002: Van Cutsem Eric; Verslype Chris; Demedts Ingrid
The treatment of advanced colorectal cancer: where are we now and where do we go?
Best practice & research. Clinical gastroenterology 2002;16(2):319-30.
2002: Tejpar Sabine; Van Cutsem Eric
Molecular and genetic defects in colorectal tumorigenesis.
Best practice & research. Clinical gastroenterology 2002;16(2):171-85.
2002: De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
European journal of nuclear medicine and molecular imaging 2002;29(4):525-9.
2002: Van Cutsem E; Hoff P M; Blum J L; Abt M; Osterwalder B
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):484-5.
2002: Flamen P; Van Cutsem E; Lerut A; Cambier J P; Haustermans K; Bormans G; De Leyn P; Van Raemdonck D; De Wever W; Ectors N; Maes A; Mortelmans L
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):361-8.
2002: Anak O; Van Cutsem E; Nordlinger B
The EORTC Gastrointestinal Tract Cancer Group: 40 years of research contributing to improved GI cancer management.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 4():S65-70.
2002: Van Cutsem Eric; Haller Daniel; Ohtsu Atsushi
The role of chemotherapy in the current treatment of gastric cancer.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2002;5 Suppl 1():17-22.
2002: Abell Thomas L; Van Cutsem Eric; Abrahamsson Hasse; Huizinga Jan D; Konturek J W; Galmiche Jean Paul; VoelIer Guy; Filez Ludo; Everts Bernt; Waterfall William E; Domschke W; Bruley des Varannes Stanislas; Familoni Babajide O; Bourgeois Ivan M; Janssens Jozef; Tougas Gervais
Gastric electrical stimulation in intractable symptomatic gastroparesis.
Digestion 2002;66(4):204-12.
2001: Van Cutsem E; Dicato M; Wils J
Recent advances in the management of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2302-9.
2001: Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel W H; Seitz J F; Thompson P; Vieitez J M; Weitzel C; Harper P;
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(21):4097-106.
2001: Tejpar S; Cassiman J J; Van Cutsem E
The molecular basis of colorectal cancer.
Acta gastro-enterologica Belgica 2001;64(3):249-54.
2001: Tejpar S; Li C; Yu C; Poon R; Denys H; Sciot R; Van Cutsem E; Cassiman J J; Alman B A
Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour).
British journal of cancer 2001;85(1):98-101.
2001: Flamen P; Hoekstra O S; Homans F; Van Cutsem E; Maes A; Stroobants S; Peeters M; Penninckx F; Filez L; Bleichrodt R P; Mortelmans L
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).
European journal of cancer (Oxford, England : 1990) 2001;37(7):862-9.
2001: Topal B; Flamen P; Aerts R; D'Hoore A; Filez L; Van Cutsem E; Mortelmans L; Penninckx F
Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2001;27(2):175-9.
2001: Van Cutsem E; Cunningham D; Hoff P M; Maroun J
Thymidine phosphorylase (TP) activation: convenience through innovation.
The oncologist 2001;6 Suppl 4():1-2.
2000: Lerut T; Flamen P; Ectors N; Van Cutsem E; Peeters M; Hiele M; De Wever W; Coosemans W; Decker G; De Leyn P; Deneffe G; Van Raemdonck D; Mortelmans L
Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy.
Annals of surgery 2000;232(6):743-52.
2000: Flamen P; Lerut A; Van Cutsem E; Cambier J P; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
The Journal of thoracic and cardiovascular surgery 2000;120(6):1085-92.
2000: Van Cutsem E; Peeters M
Oral fluoropyrimidines in colorectal cancer.
Seminars in oncology 2000;27(5 Suppl 10):91-5.
2000: Flamen P; Van Cutsem E; Mortelmans L
A new imaging technique for colorectal cancer: positron emission tomography.
Seminars in oncology 2000;27(5 Suppl 10):22-9.
2000: Flamen P; Lerut A; Van Cutsem E; De Wever W; Peeters M; Stroobants S; Dupont P; Bormans G; Hiele M; De Leyn P; Van Raemdonck D; Coosemans W; Ectors N; Haustermans K; Mortelmans L
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(18):3202-10.
2000: Van Cutsem E; Findlay M; Osterwalder B; Kocha W; Dalley D; Pazdur R; Cassidy J; Dirix L; Twelves C; Allman D; Seitz J F; Schölmerich J; Burger H U; Verweij J
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1337-45.
2000: Van Cutsem E; Haustermans K; Van Steenbergen W
New treatment possibilities for pancreatic and biliary tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():165-9.
1999: Armand J P; Cunningham D; van Cutsem E; Misset J L; Kohne C H
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Anti-cancer drugs 1999;10 Suppl 1():S5-12.
1999: Tejpar S; Nollet F; Li C; Wunder J S; Michils G; dal Cin P; Van Cutsem E; Bapat B; van Roy F; Cassiman J J; Alman B A
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).
Oncogene 1999;18(47):6615-20.
1999: Driessen A; Ectors N; Van Cutsem E; Penninckx F; Filez L; Pittaluga S; Delabie J; De Wolf-Peeters C; Geboes K
Different gastritis features are linked to different gastric neoplasms.
Gastroentérologie clinique et biologique 1999;23(6-7):747-53.
1999: Van Cutsem E
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
European journal of cancer (Oxford, England : 1990) 1999;35 Suppl 1():S1-2.
1999: Van Cutsem E; Peeters M; Verslype C; Filez L; Haustermans K; Janssens J
The medical treatment of colorectal cancer: actual status and new developments.
Hepato-gastroenterology 1999;46(26):709-16.
1999: Filez L; Penninckx F; Ectors N; Van Cutsem E; Geboes K; Aerts R; D'Hoore A; Kerremans R
Radioimmunoguided surgery for colorectal carcinoma.
Hepato-gastroenterology 1999;46(26):691-700.
1999: Haustermans K; Fowler J; Geboes K; Lerut A; Van Cutsem E; Begg A
Cell kinetic measurements: principles, guidelines for treatment?
Hepato-gastroenterology 1999;46(26):670-8.
1999: Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):894-901.
1999: Van Cutsem E; Blijham G H
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Seminars in oncology 1999;26(1 Suppl 5):13-20.
1999: Van Cutsem E; Cunningham D; Ten Bokkel Huinink W W; Punt C J; Alexopoulos C G; Dirix L; Symann M; Blijham G H; Cholet P; Fillet G; Van Groeningen C; Vannetzel J M; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
European journal of cancer (Oxford, England : 1990) 1999;35(1):54-9.
1999: Stockx L; Raat H; Caerts B; Van Cutsem E; Wilms G; Marchal G
Transcatheter embolization of hepatic arteriovenous fistulas in Rendu-Osler-Weber disease: a case report and review of the literature.
European radiology 1999;9(7):1434-7.
1998: Van Cutsem E; Pozzo C; Starkhammar H; Dirix L; Terzoli E; Cognetti F; Humblet Y; Garufi C; Filez L; Gruia G; Cote C; Barone C
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(11):1199-204.
1998: Driessen A; Ectors N; Creemers J; Filez L; Penninckx F; Van Cutsem E; Geboes K
Intestinal metaplasia in gastric malignancy: a comparison between carcinoma and lymphoma.
European journal of gastroenterology & hepatology 1998;10(7):595-600.
1998: Wilmer A; Van Cutsem E; Andrioli A; Tack J; Coremans G; Janssens J
Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying.
Gut 1998;42(2):235-42.
1998: de Goede E; Filez L; Janssens J; Van Cutsem E
Follow-up of colon cancer: detection of liver metastases: benefit and periodicity.
Acta gastro-enterologica Belgica 1998;61(1):8-10.
1997: Lissens P; Filez L; Aerts R; D'Hoore A; Van Cutsem E; Ectors N; Penninckx F; Kerremans R
Surgery for gastric remnant carcinoma following Billroth II gastrectomy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1997;23(6):518-21.
1997: Van Cutsem E
Future developments with 'Tomudex' (raltitrexed).
Anti-cancer drugs 1997;8 Suppl 2():S33-8.
1996: Van Cutsem E; Piessevaux H
Pharmacologic therapy of arteriovenous malformations.
Gastrointestinal endoscopy clinics of North America 1996;6(4):819-32.
1996: Van Cutsem E
A glimpse of the future. new directions in the treatment of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 5():S23-7.
1995: Van Cutsem E; Tejpar S; Rutgeerts P; Janssens J
Screening for colorectal cancer.
Acta gastro-enterologica Belgica 1995;58(5-6):397-404.
1995: Van Cutsem E; Fevery J
Pancreatic cancer: a plea for more trials.
European journal of cancer (Oxford, England : 1990) 1995;31A(6):867-9.
1995: Van Cutsem E; Filez L; Dewyspelaere J; Penninckx F; Janssens J
Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.
Anticancer research 1995;15(3):1079-80.
1993: Van Cutsem E; Penninckx F; Filez L; Kerremans R; Vantrappen G
Repeated hepatic ischemia in combination with chemotherapy for liver carcinoid metastases.
Acta gastro-enterologica Belgica 1993;56(3-4):292-5.
1993: Van Cutsem E
Georges Brohee Prize. Oestrogen-progesterone, a new therapy of bleeding gastrointestinal vascular malformations.
Acta gastro-enterologica Belgica 1993;56(1):2-10.
1992: Annese V; Janssens J; Vantrappen G; Tack J; Peeters T L; Willemse P; Van Cutsem E
Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination.
Gastroenterology 1992;102(3):823-8.
1992: Peeters T L; Muls E; Janssens J; Urbain J L; Bex M; Van Cutsem E; Depoortere I; De Roo M; Vantrappen G; Bouillon R
Effect of motilin on gastric emptying in patients with diabetic gastroparesis.
Gastroenterology 1992;102(1):97-101.
1990: Urbain J L; Van Cutsem E; Siegel J A; Mayeur S; Vandecruys A; Janssens J; De Roo M; Vantrappen G
Visualization and characterization of gastric contractions using a radionuclide technique.
The American journal of physiology 1990;259(6 Pt 1):G1062-7.
1990: Urbain J L; Penninckx F; Siegel J A; Vandenborre P; Van Cutsem E; Vandenmaegdenbergh V; De Roo M
Effect of proximal vagotomy and Roux-en-Y diversion on gastric emptying kinetics in asymptomatic patients.
Clinical nuclear medicine 1990;15(10):688-91.
1990: Urbain J L; Vantrappen G; Janssens J; Van Cutsem E; Peeters T; De Roo M
Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(9):1490-3.
1990: van Cutsem E; Rutgeerts P; Vantrappen G
Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone.
Lancet 1990;335(8695):953-5.
1989: Urbain J L; Siegel J A; Mortelmans L; van Cutsem E; van den Maegdenbergh V; de Roo M
Effect of solid-meal caloric content on gastric emptying kinetics of solids and liquids.
Nuklearmedizin. Nuclear medicine 1989;28(4):120-3.
1988: Van Cutsem E; Rutgeerts P; Geboes K; Van Gompel F; Vantrappen G
Estrogen-progesterone treatment of Osler-Weber-Rendu disease.
Journal of clinical gastroenterology 1988;10(6):676-9.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Eric Van Cutsem

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Eric Van Cutsem (preview)

All Publications